
By: **Delegates Pendergrass, Bobo, Goldwater, Holmes, Howard, Hubbard,
Madaleno, Mandel, Marriott, McHale, and F. Turner**

Introduced and read first time: January 20, 2006

Assigned to: Health and Government Operations

A BILL ENTITLED

1 AN ACT concerning

2 **Health - Clinical Trials Data Bank**

3 FOR the purpose of requiring a certain sponsor to submit to the Clinical Trials Data
4 Bank of the U.S. Department of Health and Human Services certain
5 information regarding a certain clinical trial before the sponsor may permit any
6 person to enroll participants in the clinical trial; providing for a certain
7 exception; prohibiting a person from conducting a clinical trial in violation of
8 this Act; providing that this Act may not be construed to affect certain existing
9 statutory requirements; authorizing the Office of the Attorney General to seek
10 certain relief to prevent the conduct of a clinical trial in violation of this Act;
11 requiring the Office to report to the General Assembly, on or before a certain
12 date and annually thereafter, on certain violations and on certain actions of the
13 Office; defining certain terms; and generally relating to the submission of
14 information regarding clinical trials to the Clinical Trials Data Bank.

15 BY adding to

16 Article - Health - General

17 Section 13-2301 through 13-2305 to be under the new subtitle "Subtitle 23.

18 Clinical Trials Data Bank"

19 Annotated Code of Maryland

20 (2005 Replacement Volume and 2005 Supplement)

21 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF

22 MARYLAND, That the Laws of Maryland read as follows:

23 **Article - Health - General**

24 **SUBTITLE 23. CLINICAL TRIALS DATA BANK.**

25 13-2301.

26 (A) IN THIS SUBTITLE THE FOLLOWING WORDS HAVE THE MEANINGS

27 INDICATED.

1 (B) "CLINICAL TRIAL" MEANS A CLINICAL TRIAL TO TEST THE EFFECTIVENESS
2 OF DRUGS, INCLUDING BIOLOGICAL DRUG PRODUCTS, TO TREAT SERIOUS OR
3 LIFE-THREATENING DISEASES AND CONDITIONS CONDUCTED UNDER THE U.S. FOOD
4 AND DRUG ADMINISTRATION'S INVESTIGATIONAL NEW DRUG REGULATIONS (23 CFR
5 PART 312).

6 (C) "DATA BANK" MEANS THE CLINICAL TRIALS DATA BANK IN THE U.S.
7 DEPARTMENT OF HEALTH AND HUMAN SERVICES ESTABLISHED UNDER § 113 OF THE
8 FEDERAL FOOD AND DRUG ADMINISTRATION MODERNIZATION ACT OF 1997.

9 (D) "SERIOUS OR LIFE-THREATENING DISEASE OR CONDITION" MEANS A
10 DISEASE OR CONDITION THAT HAS BEEN IDENTIFIED OR DESCRIBED AS SERIOUS OR
11 LIFE-THREATENING IN THE PUBLISHED GUIDANCE OF THE U.S. FOOD AND DRUG
12 ADMINISTRATION RELATING TO THE CLINICAL TRIALS DATA BANK.

13 (E) "SPONSOR" MEANS THE PERSON THAT HOLDS THE INVESTIGATIONAL NEW
14 DRUG EXEMPTION UNDER WHICH A CLINICAL TRIAL WILL BE CONDUCTED IN
15 ACCORDANCE WITH APPLICABLE REGULATIONS OF THE U.S. FOOD AND DRUG
16 ADMINISTRATION.

17 13-2302.

18 NOTHING IN THIS SUBTITLE MAY BE CONSTRUED TO AFFECT THE
19 REQUIREMENTS UNDER SUBTITLE 20 OF THIS TITLE.

20 13-2303.

21 (A) EXCEPT AS PROVIDED IN SUBSECTION (B) OF THIS SECTION, A SPONSOR
22 MAY NOT PERMIT ANY PERSON TO ENROLL A PARTICIPANT IN A CLINICAL TRIAL IN
23 THE STATE UNLESS, NOT LATER THAN 21 DAYS AFTER A CLINICAL TRIAL HAS BEEN
24 OPENED TO ENROLLMENT, THE SPONSOR HAS SUBMITTED TO THE DATA BANK:

25 (1) A DESCRIPTION OF THE PURPOSE OF AN EXPERIMENTAL DRUG USED
26 IN THE CLINICAL TRIAL;

27 (2) THE ELIGIBILITY CRITERIA FOR PARTICIPATION IN THE CLINICAL
28 TRIAL;

29 (3) A DESCRIPTION OF THE LOCATION OF CLINICAL TRIAL SITES IN THE
30 STATE; AND

31 (4) IDENTIFICATION OF A POINT OF CONTACT FOR INDIVIDUALS WHO
32 WANT TO ENROLL IN THE CLINICAL TRIAL.

33 (B) IF A CLINICAL TRIAL IS EXEMPT FROM LISTING IN THE DATA BANK
34 BECAUSE THE SPONSOR OF THE CLINICAL TRIAL HAS SUBMITTED A DETAILED
35 CERTIFICATION TO THE SECRETARY OF HEALTH AND HUMAN SERVICES AS
36 AUTHORIZED BY § 113 OF THE FEDERAL FOOD AND DRUG ADMINISTRATION
37 MODERNIZATION ACT OF 1997, THE SPONSOR NEED NOT SUBMIT THE INFORMATION
38 SPECIFIED IN SUBSECTION (A) OF THIS SECTION.

1 13-2304.

2 (A) A PERSON MAY NOT CONDUCT A CLINICAL TRIAL IN VIOLATION OF THIS
3 SUBTITLE.

4 (B) THE OFFICE OF THE ATTORNEY GENERAL MAY SEEK APPROPRIATE
5 INJUNCTIVE OR OTHER RELIEF TO PREVENT THE CONDUCT OF A CLINICAL TRIAL IN
6 VIOLATION OF THIS SUBTITLE.

7 13-2305.

8 ON OR BEFORE DECEMBER 31, 2007, AND ANNUALLY THEREAFTER, THE OFFICE
9 OF THE ATTORNEY GENERAL SHALL REPORT, IN ACCORDANCE WITH § 2-1246 OF THE
10 STATE GOVERNMENT ARTICLE, TO THE GENERAL ASSEMBLY ON THE NUMBER AND
11 TYPES OF VIOLATIONS OF THIS SUBTITLE THAT OCCURRED DURING THE PREVIOUS
12 CALENDAR YEAR AND THE ACTIONS TAKEN BY THE OFFICE IN RESPONSE TO THE
13 VIOLATIONS.

14 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect
15 October 1, 2006.